This is the "Home" page of the "Grand Rounds 10/01/14 @ BID-Needham: Dr. Abraham Morgentaler" guide.
Alternate Page for Screenreader Users
Skip to Page Navigation
Skip to Page Content

Grand Rounds 10/01/14 @ BID-Needham: Dr. Abraham Morgentaler  

Testosterone Therapy: Advances and Controversies
Last Updated: Aug 19, 2016 URL: http://bidmc.libguides.com/Morgentaler Print Guide RSS Updates
Home Print Page
  Search: 
 

Speaker: Date: Topic

Abraham Morgentaler, MD, FACS

Oct 1, 2014

Testosterone Therapy: Advances and Controversies

      

    Responsibility for Content

    The WebEx video, take-away points, and article links were sent by the Medical Library and the CME Committee.

    Diane E. Young, Information Specialist

    dyoung3@bidmc.harvard.edu

     

        

      Take-Away Points of the Presentation

      "With increased recognition of the benefits of testosterone (T) therapy for middle-aged men, there has been a concomitant reexamination of the historical fear that raising T will result in more prostate cancer (PCa). Studies have failed to show increased risk of PCa in men with higher serum T, and supraphysiologic T fails to increase prostate volume or prostate-specific antigen in healthy men. This apparent paradox is explained by the Saturation Model, which posits a finite capacity of androgen to stimulate PCa growth. Modern studies indicate no increased risk of PCa among men with serum T in the therapeutic range."  (Quoted from Article No. 3; see articles below.)

          

        WebEx Video of the Presentation

         

        Feedback Welcome

        Was this information helpful?

        How useful is this page?
        (1 = Not Useful, 5 = Very Useful!)

        Additional comments:


        Your Email:


        THIS SITE IS MAINTAINED BY KNOWLEDGE SERVICES AT THE BETH ISRAEL DEACONESS MEDICAL CENTER.
        CLICK HERE TO ASK A QUESTION OR REPORT A PROBLEM.

        Description

        Loading  Loading...

        Tip